Site updated at Wednesday, 22 June 2016

Living with Dementia

Amyloid beta in the brain of individuals with Alzheimer’s disease

  • - Dementia News
  • Mar 30, 2012
  • Comments
  • Viewed: 890
Tags: | alzheimer's disease | amyloid beta | amyloid beta 42 |

The deposition of amyloid beta in the brain of individuals with Alzheimer’s disease is the focus of much research into both its cause and treatment.

While there may not be a consensus as to whether the deposition contributes to the disease or is a consequence of the disease, there is agreement that it is not favoured thermodynamically, meaning that something else is promoting the process.

Other proteins are often co-deposited in vivo with amyloid beta and one such protein is serum amyloid P component (or SAP). Recent evidence has suggested that SAP is elevated in Alzheimer’s disease and a team of researchers from Keele University in Staffordshire, UK, led by Professor Chris Exley, has shown that physiologically-significant concentrations of SAP promote the deposition of amyloid beta under conditions approaching those found in vivo.

Professor Exley said: “We have shown that SAP is bound by fibrils of amyloid beta and that this interaction stabilises the fibrils over timescales which are physiologically significant. This is the first example of a physiologically significant biomolecule promoting and stabilising the formation of amyloid fibrils of amyloid beta 42 under near-physiological conditions.”

The group also found that this property of SAP was enhanced in the presence of aluminium, a metal which has also been shown to be co-deposited with amyloid beta in Alzheimer’s disease. There have been recent efforts to reduce the plasma concentration of SAP as a therapy for Alzheimer’s disease and the research provides strong evidence that SAP is involved in the deposition of amyloid beta 42 in Alzheimer’s disease and that by reducing the plasma concentration of SAP it might also reduce the deposition of amyloid beta. Their observations support serum amyloid P component as a therapeutic target in Alzheimer’s disease.


Chris Stone
.(JavaScript must be enabled to view this email address)
IOS Press

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]

Your details

* Required field

Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

Living With Dementia

dementia symptoms3 - neuroscience2 - cell biology1 - app3 - cardiovascular risk factors1 - fish oil supplements1 - amyloid β1 - mental confusion4 - alzheimer's disease risk3 - blood sugar3 - zilboorg1 - encephalopathy-alcoholic10 - burden of dementia1 - misplacing things1 - symptomatic benefit1 - gray matter1 - early alzheimer's damage1 - physical discomfort1 - misplacing items1 - decline in memory1 - biomarkers of alzheimer's disease1 - video game1 - mycobacterium tuberculosis1 - learning skills1 - paraphrenia1 - dementia community1 - huntingtin1 - psychotic symptoms1 - symptoms of dementia3 - rigidity1 -